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ABSTRACT 
Background: Hepatitis B virus (HBV) is widely distributed all over the world. Quite a large number of 
the population worldwide is exposed to the virus. It is estimated that 378 million are chronically 
infected and at risk of developing serious complications like liver cirrhosis and hepatocelluar 
carcinoma leading to death. Fortunately, an effective vaccine has been introduced to prevent infection 
with the virus. The rate of infection by HBV has been effectively reduced by universal vaccination with 
that vaccine. Post-vaccination concentration of vaccine induced neutralizing antibodies against HBsAg 
above 10 mlU is considered protective against the virus.  
Objectives: To assess the state of immunization of Sudanese individuals previously vaccinated by 
HBV vaccine in Khartoum State. 
Methodology: A total of 90 individuals previously vaccinated with HBV vaccine and 70 unvaccinated 
persons (control) had their blood tested anti-HBsAg. Specimens negative for anti-HBs Ag were further 
tested for total (IgM & IgG) anti-HBcAg and HBsAg by ELISA. Specimens positive for total anti-
HBcAg were further tested for IgM anti-HBcAg. 
Results: The majority 76(88.4%) of the vaccinated subjects and 4.28% of the control were found to be 
positive for anti-HBsAg. Out of the 76 subjects with positive antibody response; 68.4% showed good 
antibody response (protected against the virus). The remaining (31.6%) showed low antibody response 
and are therefore at risk of infection. In general 42.2% of the vaccinated subjects and all the control 
group revealed low or no antibody response and are at risk of infection. The results of this study 
showed statistically significant difference in the antibody response between those who received three 
vaccine doses (72.7%) and one dose (18.8%) with P value < 0.05. Two (2.22%) of the vaccinated 
subjects have developed HBV infection, compared to four (5.71%) of the control group. 
Conclusion: Antibody response to HBV vaccine was found 88.4% of the vaccinated subjects, 
however, considerable number of the vaccinated subjects revealed low or no antibody response. 
Individuals, who received three doses of the vaccine, had statistically significant antibody response 
than those who received only one dose.   
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epatitis B virus is an ubiquitous virus 
with a global distribution1. It is one of 
the  world's  most common               
and     serious      infectious        agents. 
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Over 2 billion people worldwide have been 
exposed to hepatitis B virus (HBV) infection 
and at least 378 million are chronically infected 
and at risk of severe disease and death. Nearly 
25% of all carriers develop liver cancer and 
liver cirrhosis. HBV infection causes more than 
one million deaths every year1-3.  Studies 
conducted in Sudan revealed high prevalence of 
HBV infection4. 
HBV infection rate has been effectively 
reduced by universal vaccination. 
Concentrations of vaccine-induced neutralizing 
H 
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antibodies (anti-HBsAg) above 10 mlU are 
generally regarded as sufficient for protection 
against the virus5. The duration of protection 
provided by hepatitis B vaccination is yet 
unknown, but the presence of immune memory 
cells can be evaluated indirectly by measuring 
the immune response to a booster dose of the 
vaccine. Several reports have unequivocally 
demonstrated that some individuals with 
antibodies against hepatitis B core antigen as 
the only hepatitis B virus serological marker; 
are chronic carriers for HBV6. Detection of 
hepatitis B surface antigen (HBsAg) by enzyme 
immunoassay (EIA), utilizes both polyclonal 
and/or monoclonal anti-HBsAg and target the 
major "n" determinant of HBsAg, although 
other targets may also be available for 
detection. Such assay may be unable to detect 
HBsAg "a" determinant mutants7,8. Previous 
studies conducted in Nigeria, Taiwan and Italy 
showed antibody response to HBV vaccine to 
be 61%, 75.8% and 90.3% respectively9-11. 
The aim of this study was to assess the 
immunization status of individuals vaccinated 
with HBV vaccine in Khartoum State in 




This prospective cross sectional analytical 
study was conducted during the period from 
March to May, 2012. Ninety individuals 
already vaccinated were randomly recruited to 
participate in the study irrespective of age, 
gender and duration of immunization. Immune-
compromised, patients with chronic diseases or 
on immune suppressive therapy were excluded. 
Seventy non vaccinated subjects were included 
as control group. After agreeing to be enrolled 
in the study each subject was asked to fill a 
questionnaire composing of the basic 
information such as gender, age, residence, 
duration of vaccination and number of vaccine 
doses received. Thereafter, three ml of venous 
blood were collected from each subject under 
the study and drawn into plain container, 
allowed to clot at room temperature. The 
clotted samples were centrifuged at 3000 rpm 
for five minutes. The sera were separated into 
other containers and stored in a deep freezer at -
20ْ C till tested. All the sera were then tested for 
anti-HBsAg using enzyme immune assay 
(Statfax). Specimens negative or with low titer 
of anti-HBs Ag were further tested for total 
antibody(both IgG and IgM) against hepatitis B 
core antigen (HBcAg) and hepatitis B surface 
antigen. Specimens positive for total anti-
HBcAg were tested for IgM antibody against 
the core antigen (IgM anti-HBc Ag). All the 
ELISA kits used for testing the antibodies and 
antigens were purchased from KEWEI 
company (Beijing KEWEI clinical diagnostic 
reagents INC Add: No 19, Gucheng X Rd, 
Shijing Shan District Beijing, China). 
 
RESULTS 
In this study a total of 90 individuals previously 
vaccinated with HBV vaccine with mean age 
27.58 years, range 12 - 70 years were included. 
Additional 70 unvaccinated subjects with mean 
age 32.2 years, range 16 - 70 years were 
included as control. 
Among the vaccinated group, the majority 
(88.4%) showed antibody response and a 
remarkable number (14/ 90) were found to be 
negative for anti-HBsAg (non-responders) 
(Figure 1). Out of the vaccinated individuals 
with positive antibodies against HBsAg, 
52(68.42%) showed good response to vaccine 
(protected against HBV infection) and the rest 
(31.58%) revealed poor antibody response (at 
risk of infection). On the other hand only 
3(4.28%) of the unvaccinated (control) group 
were found to be positive for antibodies against 
HBsAg and all revealed poor response to the 
vaccine (Table 1). 
Antibody response to HBV vaccine was found 
to be statistically better in the vaccinated group 
compared to the controls (P value< 0.05). 
Antibody response was good in 72.7% of those 
who received 3 doses of the vaccine compared 
to 18.8% of those who received only one dose  
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Fig 1: immunization status of vaccinated subjects (n=90) 
 
     Table 1: Immunization status of the unvaccinated group 
Antibody response status Frequency Percentage 
No response 67 95.71 
Poor response 3 4.28 
Good response 0 0 
Total 70 100 
 
 
(Table 2). Childhood immunization with 
HBV vaccine (3 doses) was found to be 
better regarding antibody response to the 
vaccine. These findings revealed statistically 
significant correlation between antibody 
response and number of vaccine doses 
received (P value<0.05). 
Two (2.22%) of the vaccinated subjects and 
four (5.71%) of unvaccinated were found to 
be positive for HBsAg. 
 
DISCUSSION 
The majority (88.4%) of the vaccinated 
subjects included in this study showed 
antibody response to the vaccine (≥ 10 mlU/ 
ml). However a considerable percentage 
(14.6%) is non-responders (without antibody 
response). Out of those with antibody 
response to the vaccine, 68.4% showed good 
response (immune) and the rest (31.6%) 
poor response (low immunity). In the 
control group, only 4.28% were found to 
have antibodies against HBsAg, all of them  
have low antibody levels (not protected). 
The obtained results reveal statistically 
significant variation in the antibody 
response between the studied population and 
the control groups (P value < 0.05). 
 
 
Table 2: Immunization status of the vaccinated individuals according to the number of received doses 
of HBV vaccine 
Number of 
vaccine doses 
Total tested No Ab. response Poor Ab. response Good Ab.response 
Freq Percent Freq Percent Freq Percent 
1 16 3 18.75 10 62.50 3 18.75 
2 27 7 25.92 5 18.51 15 55.55 
3 44 4 9.00 8 18.18 32 72.72 
3(childhood) 3 0 0.00 1 33.33 2 66.66 
Total 90 14 55.55 24 26.66 52 57.77 
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The results of the current study are in 
agreement with a study conducted by Odusanya 
and his coworkers in Nigeria. They reported 
that 61% of vaccinated subjects developed 
protective  antibodies  compared  to  18% for 
the control group9. In Taiwan, Yen-Hsuan and 
his colleagues reported HBsAg seropositivity   
of 75.8% and 70.7% among persons younger 
than 15years and between 15 -20 years 
respectively10. Higher antibody response 
(90.32%) was reported in Italy by Campagna 
and his companion11.The variation in the 
antibody response in these studies can be 
attributed to the study populations with regards 
to age, residence, economical and atmospheric 
conditions and possibly vaccines qualities. 
Remarkable number of vaccinated persons did 
not show antibody response to the vaccine. This 
may be due to problems in the vaccination 
process as it is observed that some persons 
received only one vaccine dose more over some 
of them might had immunity defects. Two 
(2.22%) of vaccinated group and four (5.71%) 
of the control group were found positive for 
HBsAg. This finding is comparable with the 
figure reported by Voranush Chongsrisawat et 
al in Thailand, who reported HBsAg rate of 4% 
among vaccinated children12. Figures from 
Nigeria were 2% and 11.8% for vaccinated and 
unvaccinated groups respectively9. 
 
CONCLUSION 
Remarkable percentage of HBV vaccinated 
persons showed no or poor antibody response 
to the vaccine and therefore at risk of infection 
by HBV. In fact some of them were found to be 
infected evidenced by detection of HBsAg in 
their blood. A considerable number of 
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